Arbutus Biopharma Caps $230M Tender at $5.00 a Share

Arbutus Biopharma Corporation (Nasdaq: ABUS) said on 30 September 2026 that it expects to take up and pay for 46,000,000 common shares at US$5.00 each under its modified Dutch auction tender offer, an aggregate purchase price of US$230 million before fees and expenses. The offer expired at 5:00 p.m. New York City time on 29 September 2026. The company said the bought-back shares represent roughly 23 percent of its issued and outstanding stock as of the close of business that day.

Context — why a cash tender matters for a clinical-stage biotech

Arbutus carries no marketed product. The company said it is a clinical-stage biopharmaceutical company focused on infectious disease, developing imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) for chronic hepatitis B infection. For a business at that stage, a US$230 million return of capital is a balance-sheet event rather than an operating one.

The report gives no prior-period comparable. It does not disclose a previous buyback, an earlier tender, or the cash position that funds this one. What it does give is the ownership arithmetic that follows. Immediately after completion, the company anticipates approximately 153,275,907 shares will be issued and outstanding.

That is the number that sets the new float. Every per-share figure a reader might care about — cash per share, book value per share, the ownership stake of any remaining holder — gets recalculated against roughly 153.3 million shares instead of the count outstanding before the offer.

The catalyst chain is mechanical. Arbutus priced the auction between US$5.00 and US$5.75 per share, set an expiry, and the depositary counted the tenders. Demand came in above the cap, so the clearing price landed at the bottom of the range. The company got the full US$230 million it sought, at the cheapest permitted price.

Data — what the numbers show

TSX Trust Company, acting as depositary, produced the preliminary count. Arbutus said 65,907,215 shares were validly tendered and not properly withdrawn through auction tenders at or below the purchase price and through purchase price tenders.

That is the oversubscription. The company intends to buy 46,000,000 shares, so it will not take everything offered. Arbutus expects shareholders in those categories to have approximately 55 percent of their tendered shares purchased, with the remainder returned. Odd-lot tenders sit outside proration.

Item	Preliminary figure
Purchase price	US$5.00 per share
Shares taken up	46,000,000
Aggregate purchase price	US$230 million
Shares validly tendered	65,907,215
Expected proration	~55 percent
Shares outstanding after	~153,275,907

A separate pool covers proportionate tenders. Arbutus said 9,307,231 shares are anticipated to be taken up under proportionate tenders, which are purchased apart from the main pool and are not subject to proration. Shareholders who tendered above US$5.00 should not expect any of those shares to be bought.

The report offers no peer or sector comparison, and no index or yield level to anchor the pricing against.

Analysis — who is left holding the smaller register

Roivant Sciences Ltd. is the reference point for ownership. Arbutus said Roivant beneficially owned 38,847,462 shares, about 19.5 percent of the register as of 29 September 2026, and made a proportionate tender. After completion it expects to hold approximately 19.5 percent again.

The proportionate pool is what makes that possible. A holder that tenders proportionately sells into a ring-fenced pool sized to its stake, so the buyback shrinks the register without diluting or concentrating that holder. Everyone in the auction pool absorbs the 55 percent proration instead.

The counter-argument sits in the price. Arbutus accepted US$5.00, the floor of its own US$5.00 to US$5.75 range, which tells you where the marginal seller sat. A register willing to clear at the bottom of the band is a register that wanted out more than it wanted the top of the range.

The second-order effect lands on the remaining holders, not on the sector. Arbutus is a single clinical-stage name with no marketed revenue, so the tender reshapes its own capital structure and touches no peer. The flow is one-directional: shares move from tendering holders to cancellation, and Roivant's proportional position is preserved by construction rather than by purchase. Positioning after settlement is a smaller float in the hands of whoever declined to tender at US$5.00.

Outlook — what to watch next

Everything disclosed so far is preliminary. Arbutus said the share count, the proration factor, the post-offer register and the purchase price all remain subject to verification by the depositary, and rest on the assumption that shares tendered through notice of guaranteed delivery arrive within the one trading-day settlement period.

The company said it will issue a press release with the final results, including the final proration factor and the final purchase price, after take-up and payment. Payment for accepted shares follows promptly under the offer terms, and the depositary returns all other tendered shares.

No date was given for that final release. The offer documents themselves — the offer to purchase and issuer bid circular dated 24 August 2026, the letter of transmittal and the notice of guaranteed delivery — were filed on SEDAR+ and EDGAR.

Frequently Asked Questions

What does the Arbutus tender offer mean for retail shareholders?

Retail holders who tendered at or below US$5.00 should expect roughly 55 percent of those shares bought, with the rest returned, unless they tendered as an odd lot. Anyone who tendered above US$5.00 keeps everything. The buyback removes about 23 percent of the register, so remaining holders own a larger proportional slice of a company with US$230 million less cash.

Why did the Arbutus buyback price settle at US$5.00?

Because the auction was oversubscribed. Arbutus set a range of US$5.00 to US$5.75 and said 65,907,215 shares were validly tendered against the 46,000,000 it intends to buy. In a modified Dutch auction the company pays the lowest price that lets it buy the number of shares it wants, so a surplus of sellers pushes the clearing price to the floor.

What happens next for Arbutus shares after the offer closes?

Arbutus will publish final results once the depositary verifies the count, then pay for accepted shares and have the rest returned. The company said it anticipates approximately 153,275,907 shares outstanding afterward. Roivant Sciences is expected to hold about 19.5 percent again, unchanged from its pre-offer stake, because it used the proportionate tender route.

Bottom Line

Arbutus is retiring 23 percent of its register at the floor of its own range, with Roivant's stake untouched.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.